We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

COLBUN:BCSColbun SA Registered Shs Analysis

Data as of 2026-03-17 - not real-time

CLP 131.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Colbún is trading at 131 CLP, well under its 20‑day (≈137), 50‑day (≈143) and 200‑day (≈146) simple moving averages, signaling a short‑term bearish momentum. The 14‑day RSI of 36.9 and a bearish MACD histogram reinforce the downside bias, while the price sits just above a key support level near 128 CLP.
On the valuation side, the stock’s trailing PE of 13.4 is markedly below the industry average of 23.4, and the forward PE of 8.7 suggests earnings growth ahead. Analysts’ consensus targets around 171 CLP imply roughly 30 % upside, and the DCF model also flags a similar upside potential. A dividend yield of 4.17 % with a 55 % payout ratio provides solid income, though the company carries a high debt‑to‑equity ratio of ~79 % and a price‑to‑book of 708, reflecting significant leverage and a market premium on regulated assets. Volatility is elevated at 27 % over the past 30 days, yet beta is low (≈0.3), indicating limited market‑wide price swings. Overall, the blend of undervalued earnings multiples, attractive dividend, and sizable upside buffer the near‑term technical weakness, positioning Colbún as a value‑oriented play with income appeal.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price hovering just above support
  • bearish technical indicators (RSI, MACD)
  • high dividend yield offering downside cushion

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • significant upside to analyst target (~30%)
  • trailing PE well below industry average
  • stable operating cash flow supporting dividend sustainability

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • regulated utility business with predictable cash flows
  • attractive dividend yield and low beta
  • valuation gap indicated by low PE and DCF upside

Key Metrics & Analysis

Financial Health

Revenue Growth2.10%
Profit Margin11.73%
P/E Ratio13.4
ROE5.77%
ROA2.49%
Debt/Equity78.80
P/B Ratio708.1
Op. Cash FlowCLP476.9M
Free Cash FlowCLP-42372752
Industry P/E23.4

Technical Analysis

TrendBearish
RSI36.9
SupportCLP 128.01
ResistanceCLP 147.73
MA 20CLP 137.39
MA 50CLP 143.18
MA 200CLP 145.92
MACDBearish
VolumeStable
Fear & Greed Index79.45

Valuation

Fair ValueCLP 0.19
Target PriceCLP 171.30
Upside/Downside30.76%
GradeUndervalued
TypeValue
Dividend Yield4.17%

Risk Assessment

Beta0.30
Volatility27.49%
Sector RiskLow
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.